Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Andrew D. Moin was appointed as Director at SAB Biotherapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the Company’s Board of Directors approved the appointment of Andrew D. Moin, of Sessa Capital (Master), L.P., to the Company’s Board of Directors, effective upon the closing of the Offering.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
SAB Biotherapeutics, Inc.: Filed Certificate of Designation creating Series A-1, A-2, and A-3 Convertible Preferred Stock with specified rights, preferences, and limitations (effective 2023-10-02).
- Change
- charter amendment
- Effective
- 2023-10-02
Exact text from the filing
On October 2, 2023, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 78,000 shares of its authorized and unissued preferred stock as Series A-1 Preferred Stock, 78,000 shares as Series A-2 Preferred Stock and 252,000 shares as Series A-3 Convertible Preferred Stock
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
SAB Biotherapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at aggregate offering price of $7.5 million; aggregate exercise prices of approximately $70.5 million, (effective 2023-09-29).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain accredited investors
- Value
- aggregate offering price of $7.5 million; aggregate exercise prices of approximately $70.5 million,
- Effective
- 2023-09-29
Exact text from the filing
On September 29, 2023, SAB Biotherapeutics, Inc. (the " Company ") entered into a securities purchase agreement (the " Securities Purchase Agreement ") with certain accredited investors (the " Investors "), pursuant to which the Company agreed to issue and sell, in a private placement (the " Offering "), (i) 7,500 shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share, for an aggregate offering price of $7.5 million (the " Series A-1 Preferred Stock "), (ii) tranche A warrants (the " Preferred Tranche A Warrants ") to acquire shares of Series A-1 Preferred Stock or Series A-3 Preferred Stock, par value $0.0001 per share, for an aggregate exercise price of $70.5 million (the " Series A-3 Preferred Stock "), (iii) tranche B warrants to acquire shares of Series A-3 Preferred Stock, par value $0.0001 per share, for an aggregate exercise price of $52.0 million (the " Preferred Tranche B Warrants "), and (iv) tranche C warrants to purchase Series A-3 Preferred Stock, p
View on SEC.gov